Analysts Set Transcat, Inc. (NASDAQ:TRNS) Price Target at $110.25

by · The Cerbat Gem

Shares of Transcat, Inc. (NASDAQ:TRNS – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $110.25.

A number of brokerages have commented on TRNS. Weiss Ratings restated a “sell (d+)” rating on shares of Transcat in a research note on Monday, December 1st. Northland Capmk raised Transcat from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 23rd. Zacks Research upgraded Transcat from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 7th. HC Wainwright reaffirmed a “buy” rating and issued a $116.00 target price on shares of Transcat in a research report on Friday, August 22nd. Finally, Northland Securities set a $95.00 target price on Transcat in a research note on Thursday, October 23rd.

Read Our Latest Analysis on TRNS

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of TRNS. Polar Asset Management Partners Inc. bought a new stake in shares of Transcat during the third quarter valued at approximately $659,000. CIBC Bancorp USA Inc. bought a new position in Transcat in the 3rd quarter worth approximately $403,000. Dark Forest Capital Management LP increased its position in Transcat by 5.4% in the 3rd quarter. Dark Forest Capital Management LP now owns 30,077 shares of the scientific and technical instruments company’s stock valued at $2,202,000 after acquiring an additional 1,548 shares during the period. Verition Fund Management LLC increased its position in Transcat by 6.4% in the 3rd quarter. Verition Fund Management LLC now owns 8,982 shares of the scientific and technical instruments company’s stock valued at $657,000 after acquiring an additional 539 shares during the period. Finally, Numerai GP LLC raised its stake in Transcat by 152.9% during the 3rd quarter. Numerai GP LLC now owns 9,589 shares of the scientific and technical instruments company’s stock valued at $702,000 after acquiring an additional 5,797 shares in the last quarter. Institutional investors own 98.34% of the company’s stock.

Transcat Stock Performance

Transcat stock opened at $52.06 on Friday. The company has a market cap of $485.72 million, a PE ratio of 42.67 and a beta of 0.79. Transcat has a 12 month low of $50.23 and a 12 month high of $111.45. The company has a fifty day moving average price of $63.48 and a two-hundred day moving average price of $75.02. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.43 and a quick ratio of 2.06.

Transcat (NASDAQ:TRNS – Get Free Report) last posted its quarterly earnings results on Monday, November 3rd. The scientific and technical instruments company reported $0.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.02). Transcat had a return on equity of 6.81% and a net margin of 3.75%.The business had revenue of $82.27 million during the quarter, compared to the consensus estimate of $79.51 million. Research analysts expect that Transcat will post 2.3 earnings per share for the current year.

About Transcat

(Get Free Report)

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.

Featured Stories